Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
ConclusionsDespite the definition of a life expectancy of > 3 months as a standard inclusion criterion in clinical trials for advanced PC, a significant proportion of study patients does not survive > 3 months.Trial registration numbersNCT00440167 (AIO-PK0104), NCT01729481 (RASH), NCT01728818 (ACCEPT).
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Germany Health | Pancreas | Pancreatic Cancer | Study